A point mutation in the heavy chain complementarity-determining region 3 (HCDR3) significantly enhances the specificity of an anti-ROS1 antibody

Biochem Biophys Res Commun. 2017 Nov 4;493(1):325-331. doi: 10.1016/j.bbrc.2017.09.023. Epub 2017 Sep 6.

Abstract

The proto-oncogene tyrosine kinase ROS1 plays a key role in carcinogenesis through gene rearrangement to form a fusion protein with other genes, in which the C-terminal intracellular region of ROS1 participates. The possibility of wild type ROS1 overexpression through epigenetic regulation has been proposed. Here, we generated an antibody, 3B20, reactive to the N-terminal region of ROS1 to use it for the detection of wild type ROS1 in cancerous tissues. Using immunoblot and immunoprecipitation analyses, we found that 3B20 also reacted with heat shock proteins (Hsp)70s. Using homology searching, ROS1 and Hsp70s were found to share an identical amino acid sequence: DLGT. Using alanine mutagenesis of ROS1, the epitope was found to harbor this sequence. To modify the idiotope with the aim of selecting more specific antibodies, we introduced random mutations into the heavy chain complementarity-determining region 3 and successfully generated an antibody clone, 3B20-G1K, with a point mutation that only reacted with ROS1 in enzyme-linked immunosorbent assays, and in immunoblot and immunoprecipitation analysis. In immunohistochemical analysis using 3B20-G1K, ROS1 was found to be absent in normal lung tissues and was overexpressed in a case of lung adenocarcinoma.

Keywords: Antibody; Epitope; Mutation; ROS1; Specificity.

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics
  • Adenocarcinoma / immunology*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / genetics*
  • Antibodies, Monoclonal / immunology*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / immunology*
  • Arabidopsis Proteins / genetics*
  • Arabidopsis Proteins / immunology
  • Complementarity Determining Regions / genetics
  • Complementarity Determining Regions / immunology
  • Drug Design
  • Drug Synergism
  • Humans
  • Immunoglobulin Heavy Chains / genetics
  • Immunoglobulin Heavy Chains / immunology
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics
  • Lung Neoplasms / immunology*
  • Mutagenesis, Site-Directed / methods
  • Nuclear Proteins / genetics*
  • Nuclear Proteins / immunology
  • Point Mutation / genetics
  • Proto-Oncogene Mas
  • Proto-Oncogenes
  • Tissue Distribution
  • Tumor Cells, Cultured

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Arabidopsis Proteins
  • Complementarity Determining Regions
  • Immunoglobulin Heavy Chains
  • MAS1 protein, human
  • Nuclear Proteins
  • Proto-Oncogene Mas
  • ROS1 protein, Arabidopsis